Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants

RCT (n=4636 and 4579 live births) found that RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life.

SPS commentary:

An editorial discusses the findings of this study and also of a study that investigated nirsevimab, a recombinant human immune globulin G1 kappa monoclonal antibody, that resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalisations than placebo throughout RSV season in healthy preterm infants. It concludes overall that the results of these two trials support the development of a monoclonal antibody with an extended half-life to deliver passive immunity, as well as provide a basis for further study of nanoparticle or alternative RSV vaccines to induce a protective and durable neutralising antibody response.



New England Journal of Medicine

Resource links:


Nirsevimab study